ow-dose atropine eye drops to reduce progression of short-sightedness (myopia) in children in the United Kingdom

Phase 2

• Conditions: Myopia; Eye Diseases

• Registration Number: ISRCTN99883695
• Lead Sponsor: Belfast Health and Social Care Trust

Brief Summary

2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/31653669/ (added 05/05/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-10-25
• Last Update Posted: 15 May 2023
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 289

Inclusion Criteria

1. Aged 6-12 years (at the time of consenting)
2. Myopia of -0.5D or greater (spherical equivalent refractive error) in both eyes
3. Best-corrected distance visual acuity (BCDVA) 0.20 logMAR or better in both eyes

Exclusion Criteria

1. Children with other ocular morbidities
2. Myopia of -10D or greater in either eye
3. Astigmatism of 2D or higher in either eye
4. Amblyopia
5. Significant health problems that can compromise the ability to attend research visits or complete the trial
6. Other factors that may compromise the ability to attend the research appointments
7. Parents or children with poor understanding of the English language
8. Children enrolled in other interventional trials
9. Allergy or hypersensitivity to atropine or excipients

Study & Design

• Study Type: Interventional
• Study Design: Not specified